Blood tests for amyloid plaques are the first triage step for primary-care patients with cognitive symptoms in 2026, while Tauklarify tau PET is a follow-up brain scan that maps tau tangles. Negatives on validated blood tests reliably rule out amyloid, while positive or unclear cases still need specialist review or PET confirmation.
Tauklarify (florquinitau F18, also called MK-6240) is a brain imaging drug that lights up clumped tau protein on PET scans. Blood tests detect amyloid-related proteins in plasma, and tau PET shows where tangles have spread. The two tests answer different questions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What each test measures
- How accurate are blood tests in primary care?
- Where does Tauklarify add value over Tauvid?
- Limits primary-care patients should know
- What to ask and do next
What each test measures
The blood tests discussed here measure phosphorylated tau in plasma, often as a p-tau217 ratio linked to amyloid plaques. As reported by the U.S. FDA, the agency cleared Fujirebio's Lumipulse G pTau217/Beta-Amyloid 1-42 plasma ratio on May 16, 2025 as the first blood test to aid Alzheimer's diagnosis in adults 55 and older with signs and symptoms by detecting amyloid plaques FDA clearance notice. Tau PET uses an injected tracer and a scanner to estimate tau tangle density and spread in the brain.
According to Healio, the FDA approved Tauklarify on Aug. 14, 2026 as the second tau-PET agent for adults with cognitive impairment evaluated for Alzheimer's to identify tau tangle pathology, based on two blinded-read studies Healio approval report. Amyloid blood results point to Alzheimer's pathology being present. Tau PET helps place symptoms along the disease course and separate Alzheimer's impairment from other causes.
How accurate are blood tests in primary care?
In FDA validation summarized by Psychiatric Times, 91.7% of positive Lumipulse results had amyloid confirmed by PET or spinal fluid and 97.3% of negative results had negative PET or spinal fluid Psychiatric Times accuracy summary. Negatives work well as rule-outs, while positives carry more false alarms. A Lund University study reported at AAIC 2026 and covered by Medical Daily found clinicians using the PrecivityAD2 p-tau217 test diagnosed Alzheimer's correctly 93% of the time in primary care versus 94% with specialists, in 1,310 patients.
The Alzheimer's Association guideline covered at AAIC 2025 sets performance bars for triage and substitution use, but limits use to cognitively impaired patients in specialty care. Blood testing fits initial sorting, not final staging. A low result lowers the chance amyloid explains symptoms, while a high result moves the patient toward confirmatory review.
Where does Tauklarify add value over Tauvid?
Tauvid (flortaucipir F18, approved in 2020) was the first tau-PET tracer for cognitively impaired adults evaluated for Alzheimer's. Practical Neurology reports studies showing 92%-100% sensitivity but wide 52%-92% specificity for estimating tangle density and distribution. Tauklarify enters as the second option in that same role.
In a head-to-head study imaging the same people with both tracers, summarized by Being Patient from The Lancet, MK-6240/Tauklarify detected tangles earlier than Tauvid and better distinguished Alzheimer's impairment with amyloid present from non-Alzheimer impairment Being Patient study summary. Earlier signal matters because tau spread tracks memory loss more closely than amyloid alone. For a patient with confirmed amyloid and unclear severity, tau PET can clarify whether Alzheimer's pathology matches the symptoms.
Limits primary-care patients should know
Blood p-tau217 can mislead when kidneys or weight alter blood levels. Reporting from Psychiatric Times and Annals of Medicine & Surgery notes severe kidney failure can cause false-positive p-tau217 and morbid obesity skews levels. About 20% of blood results fall intermediate and require PET or spinal-fluid confirmation, according to the same sources.
A positive biomarker alone also does not prove Alzheimer's is the main cause of symptoms, since amyloid and tau can coexist with vascular injury, sleep apnea, depression, or medication effects. These limits shape referrals. Primary-care doctors weigh kidney function, body weight, other brain conditions, and symptom history before ordering confirmation.
What to ask and do next
Use blood testing to decide urgency, and reserve tau PET for staging or ambiguity. Patients and families can prepare for a productive visit.
Bring a family member who sees daily function, plus prior brain scans and lab records. A clear timeline helps the doctor judge whether biomarker results match the clinical picture.
- Note onset, examples of memory or thinking change, and daily-function impact
- List kidney disease, weight change, and medicines that affect thinking
- Ask whether the blood result is negative, intermediate, or positive and what threshold the lab used
- Ask if PET or spinal-fluid confirmation, specialist referral, or watchful retesting fits the result
